[
1. Schernthaner G, Schernthaner GH. The right place for metformin today. Diabetes Res Clin Pract. 2020;159:107946. doi: 10.1016/j.diabres.2019.107946.31778746
]Open DOISearch in Google Scholar
[
2. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond). 2012;122(6):253-70.10.1042/CS20110386339886222117616
]Search in Google Scholar
[
3. Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J. 2000;348 Pt 3(Pt 3):607-14.10.1042/bj3480607
]Search in Google Scholar
[
4. Madiraju AK, Erion DM, Rahimi Y, Zhang XM, Braddock DT, Albright RA, et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature. 2014;510(7506):542-6.10.1038/nature13270407424424847880
]Search in Google Scholar
[
5. Polianskyte-Prause Z, Tolvanen TA, Lindfors S, Dumont V, Van M, Wang H, et al. Metformin increases glucose uptake and acts renoprotectively by reducing SHIP2 activity. FASEB J. 2019;33(2):2858-2869.10.1096/fj.201800529RR633864430321069
]Search in Google Scholar
[
6. Turban S, Stretton C, Drouin O, Green CJ, Watson ML, Gray A, et al. Defining the contribution of AMPactivated protein kinase (AMPK) and protein kinase C (PKC) in regulation of glucose uptake by metformin in skeletal muscle cells. J Biol Chem. 2012;287(24):20088-99.10.1074/jbc.M111.330746337019222511782
]Search in Google Scholar
[
7. Hostalek U, Gwilt M, Hildemann S. Therapeutic Use of Metformin in Prediabetes and Diabetes Prevention. Drugs. 2015;75(10):1071-94.10.1007/s40265-015-0416-8449827926059289
]Search in Google Scholar
[
8. Yerevanian A, Soukas AA. Metformin: Mechanisms in Human Obesity and Weight Loss. CurrObes Rep. 2019;8(2):156-164.10.1007/s13679-019-00335-3652018530874963
]Search in Google Scholar
[
9. Seifarth C, Schehler B, Schneider HJ. Effectiveness of metformin on weight loss in non-diabetic individuals with obesity. Exp Clin Endocrinol Diabetes. 2013;121(1):27-31.
]Search in Google Scholar
[
10. Harris K, Smith L. Safety and efficacy of metformin in patients with type 2 diabetes mellitus and chronic hepatitis C. Ann Pharmacother. 2013;47(10):1348-52.10.1177/106002801350310824259699
]Search in Google Scholar
[
11. Kuan W, Beavers CJ, Guglin ME. Still sour about lactic acidosis years later: role of metformin in heart failure. Heart Fail Rev. 2018;23(3):347-353.10.1007/s10741-017-9649-928868582
]Search in Google Scholar
[
12. Mohan M, Al-Talabany S, McKinnie A, Mordi IR, Singh JSS, Gandy SJ, et al. A randomized controlled trial of metformin on left ventricular hypertrophy in patients with coronary artery disease without diabetes: the METREMODEL trial. Eur Heart J. 2019;40(41):3409-3417.10.1093/eurheartj/ehz203682361530993313
]Search in Google Scholar
[
13. Bell S, Farran B, McGurnaghan S, McCrimmon RJ, Leese GP, Petrie JR, et al. Risk of acute kidney injury and survival in patients treated with Metformin: an observational cohort study. BMC Nephrol. 2017;18(1):163.10.1186/s12882-017-0579-5543741128526011
]Search in Google Scholar
[
14. Charytan DM, Solomon SD, Ivanovich P, Remuzzi G, Cooper ME, McGill JB, et al. Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2019;21(5):1199-1208.10.1111/dom.1364230672083
]Search in Google Scholar
[
15. Valencia WM, Palacio A, Tamariz L, Florez H. Metformin and ageing: improving ageing outcomes beyond glycaemic control. Diabetologia. 2017;60(9):1630-1638.10.1007/s00125-017-4349-5570920928770328
]Search in Google Scholar
[
16. Kasznicki J, Sliwinska A, Drzewoski J. Metformin in cancer prevention and therapy. Ann Transl Med. 2014;2(6):57.
]Search in Google Scholar
[
17. Ko EM, Walter P, Jackson A, Clark L, Franasiak J, Bolac C, et al. Metformin is associated with improved survival in endometrial cancer. Gynecol Oncol. 2014;132(2):438-42.10.1016/j.ygyno.2013.11.02124269517
]Search in Google Scholar
[
18. Feng JL, Qin X. Metformin and cancer-specific survival among breast, colorectal, or endometrial cancer patients: A nationwide data linkage study. Diabetes Res Clin Pract. 2021;175:108755. doi: 10.1016/j.diabres.2021.108755.33836207
]Open DOISearch in Google Scholar
[
19. Li K, Zhang TT, Wang F, Cui B, Zhao CX, Yu JJ, et al. Metformin suppresses melanoma progression by inhibiting KAT5-mediated SMAD3 acetylation, transcriptional activity and TRIB3 expression. Oncogene. 2018;37(22):2967-2981.10.1038/s41388-018-0172-929520103
]Search in Google Scholar
[
20. Lan B, Zhang J, Zhang P, Zhang W, Yang S, Lu D, et al. Metformin suppresses CRC growth by inducing apoptosis via ADORA1. Front Biosci (Landmark Ed). 2017;22:248-257.10.2741/448427814614
]Search in Google Scholar
[
21. Kahn BB, Alquier T, Carling D, Hardie DG. AMPactivated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab. 2005;1(1):15-25.10.1016/j.cmet.2004.12.00316054041
]Search in Google Scholar
[
22. Shaw RJ. LKB1 and AMP-activated protein kinase control of mTOR signalling and growth. Acta Physiol (Oxf). 2009;196(1):65-80.10.1111/j.1748-1716.2009.01972.x276030819245654
]Search in Google Scholar
[
23. Tian, Tian & Li, Xiaoyi & Zhang, Jinhua. mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy. International Journal of Molecular Sciences. 2019;20(3):755.10.3390/ijms20030755638704230754640
]Search in Google Scholar
[
24. Lu CC, Chiang JH, Tsai FJ, Hsu YM, Juan YN, Yang JS, et al. Metformin triggers the intrinsic apoptotic response in human AGS gastric adenocarcinoma cells by activating AMPK and suppressing mTOR/AKT signaling. Int J Oncol. 2019;54(4):1271-1281.
]Search in Google Scholar
[
25. Queiroz EA, Puukila S, Eichler R, Sampaio SC, Forsyth HL, Lees SJ, et al. Metformin induces apoptosis and cell cycle arrest mediated by oxidative stress, AMPK and FOXO3a in MCF-7 breast cancer cells. PLoS One. 2014;9(5):e98207. doi: 10.1371/journal.pone.0098207.403229324858012
]Open DOISearch in Google Scholar
[
26. Moro M, Caiola E, Ganzinelli M, Zulato E, Rulli E, Marabese M, et al. Metformin Enhances Cisplatin Induced Apoptosis and Prevents Resistance to Cisplatin in Comutated KRAS/LKB1 NSCLC. J. Thorac. Oncol. 2018;13(11):1692–1704.
]Search in Google Scholar
[
27. Zhao Y, Zhang E, Lv N, Ma L, Yao S, Yan M, et al. Metformin and FTY720 Synergistically Induce Apoptosis in Multiple Myeloma Cells. Cell. Physiol. Biochem. 2018;48:785–800.
]Search in Google Scholar
[
28. Wang L, Li K, Lin X, Yao Z, Wang S, Xiong X, et al. Metformin induces human esophageal carcinoma cell pyroptosis by targeting the miR-497/PELP1 axis. Cancer Lett. 2019;450:22-31.10.1016/j.canlet.2019.02.01430771436
]Search in Google Scholar
[
29. Man SM, Karki R, Kanneganti TD. Molecular mechanisms and functions of pyroptosis, inflammatory caspases and inflammasomes in infectious diseases. Immunol Rev. 2017;277(1):61-75.10.1111/imr.12534541682228462526
]Search in Google Scholar
[
30. Zheng Z, Bian Y, Zhang Y, Ren G, Li G. Metformin activates AMPK/SIRT1/NF-κB pathway and induces mitochondrial dysfunction to drive caspase3/GSDMEmediated cancer cell pyroptosis. Cell Cycle. 2020;19(10):1089-1104.10.1080/15384101.2020.1743911721736832286137
]Search in Google Scholar
[
31. Shida D, Takabe K, Kapitonov D, Milstien S, Spiegel S. Targeting SphK1 as a new strategy against cancer. Curr Drug Targets 2008;9:662–73.10.2174/138945008785132402267457518691013
]Search in Google Scholar
[
32. Cuvillier O, Pirianov G, Kleuser B, Vanek PG, Coso OA, Gutkind S, et al. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature. 1996;381(6585):800-3.10.1038/381800a08657285
]Search in Google Scholar
[
33. Maceyka M, Payne SG, Milstien S, Spiegel S. Sphingosine kinase, sphingosine-1-phosphate, and apoptosis. BiochimBiophys Acta. 2002;1585(2-3):193-201.10.1016/S1388-1981(02)00341-412531554
]Search in Google Scholar
[
34. Hart PC, Chiyoda T, Liu X, Weigert M, Curtis M, Chiang CY, et al. SPHK1 Is a Novel Target of Metformin in Ovarian Cancer. Mol Cancer Res. 2019;17(4):870-881.10.1158/1541-7786.MCR-18-0409644568930655321
]Search in Google Scholar
[
35. Wang X, Sun Y, Peng X, Naqvi SMAS, Yang Y, Zhang J, et al. The Tumorigenic Effect of Sphingosine Kinase 1 and Its Potential Therapeutic Target. Cancer Control. 2020;27(1):1073274820976664. doi: 10.1177/1073274820976664.848035533317322
]Open DOISearch in Google Scholar
[
36. Matsuzawa A, Nishitoh H, Tobiume K, Takeda K, Ichijo H. Physiological roles of ASK1-mediated signal transduction in oxidative stress- and endoplasmic reticulum stress-induced apoptosis: advanced findings from ASK1 knockout mice. Antioxid Redox Signal. 2002;4(3):415-25.10.1089/1523086026019621812215209
]Search in Google Scholar
[
37. Ma L, Wei J, Wan J, Wang W, Wang L, Yuan Y, et al. Low glucose and metformin-induced apoptosis of human ovarian cancer cells is connected to ASK1 via mitochondrial and endoplasmic reticulum stress-associated pathways. J Exp Clin Cancer Res. 2019;38(1):77.10.1186/s13046-019-1090-6637518730760281
]Search in Google Scholar
[
38. Yi Y, Zhang W, Yi J, Xiao ZX. Role of p53 Family Proteins in Metformin Anti-Cancer Activities. J Cancer. 2019;10(11):2434-2442.10.7150/jca.30659658434031258748
]Search in Google Scholar
[
39. Levine, A. J. p53, the cellular gatekeeper for growth and division. Cell. 1997;88(3):323-331.10.1016/S0092-8674(00)81871-19039259
]Search in Google Scholar
[
40. Haupt S, Berger M, Goldberg Z, Haupt Y. Apoptosis - the p53 network. J Cell Sci. 2003;116:4077–85.10.1242/jcs.0073912972501
]Search in Google Scholar
[
41. Yudhani RD, Astuti I, Mustofa M, Indarto D, Muthmainah M. Metformin Modulates Cyclin D1 and P53 Expression to Inhibit Cell Proliferation and to Induce Apoptosis in Cervical Cancer Cell Lines. Asian Pac J Cancer Prev. 2019;20(6):1667-1673.10.31557/APJCP.2019.20.6.1667702160631244286
]Search in Google Scholar
[
42. Chen YH, Yang SF, Yang CK, Tsai HD, Chen TH, Chou MC, et al. Metformin induces apoptosis and inhibits migration by activating the AMPK/p53 axis and suppressing PI3K/AKT signaling in human cervical cancer cells. Mol Med Rep. 2021;23(1):88.10.3892/mmr.2020.11725771642633236135
]Search in Google Scholar
[
43. Li P, Zhao M, Parris AB, Feng X, Yang X. p53 is required for metformin-induced growth inhibition, senescence and apoptosis in breast cancer cells. BiochemBiophys Res Commun. 2015;464(4):1267-1274.10.1016/j.bbrc.2015.07.11726225749
]Search in Google Scholar
[
44. Ahn HK, Lee YH, Koo KC. Current Status and Application of Metformin for Prostate Cancer: A Comprehensive Review. Int J Mol Sci. 2020;21(22):8540.10.3390/ijms21228540769814733198356
]Search in Google Scholar
[
45. Sun Y, Tao C, Huang X, He H, Shi H, Zhang Q, et al. Metformin induces apoptosis of human hepatocellular carcinoma HepG2 cells by activating an AMPK/p53/miR-23a/FOXA1 pathway. Onco Targets Ther. 2016;9:2845-53.
]Search in Google Scholar
[
46. Tran LNK, Kichenadasse G, Butler LM, Centenera MM, Morel KL, Ormsby RJ, et al. The Combination of Metformin and Valproic Acid Induces Synergistic Apoptosis in the Presence of p53 and Androgen Signaling in Prostate Cancer. Mol Cancer Ther. 2017;16(12):2689-2700.10.1158/1535-7163.MCT-17-007428802253
]Search in Google Scholar
[
47. Ben Sahra I, Laurent K, Giuliano S, Larbret F, Ponzio G, Gounon P, et al. Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res. 2010;70(6):2465-75.10.1158/0008-5472.CAN-09-278220215500
]Search in Google Scholar
[
48. Feng Y, Ke C, Tang Q, Dong H, Zheng X, Lin W, et al. Metformin promotes autophagy and apoptosis in esophageal squamous cell carcinoma by downregulating Stat3 signaling. Cell Death Dis. 2014;5(2):e1088. doi: 10.1038/cddis.2014.59.394427124577086
]Open DOISearch in Google Scholar
[
49. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009;9(11):798-809.10.1038/nrc2734485602519851315
]Search in Google Scholar
[
50. Nielsen M, Kaestel CG, Eriksen KW, Woetmann A, Stokkedal T, Kaltoft K, et al. Inhibition of constitutively activated Stat3 correlates with altered Bcl-2/Bax expression and induction of apoptosis in mycosis fungoides tumor cells. Leukemia. 1999;13(5):735-8.10.1038/sj.leu.240141510374878
]Search in Google Scholar
[
51. Deng XS, Wang S, Deng A, Liu B, Edgerton SM, Lind SE, et al. Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers. Cell Cycle. 2012;11(2):367-76.10.4161/cc.11.2.1881322189713
]Search in Google Scholar
[
52. Griffiths CL, Olin JL. Triple negative breast cancer: a brief review of its characteristics and treatment options. J Pharm Pract. 2012;25(3):319-23.10.1177/089719001244206222551559
]Search in Google Scholar
[
53. Tomic T, Botton T, Cerezo M, Robert G, Luciano F, Puissant A, et al. Metformin inhibits melanoma development through autophagy and apoptosis mechanisms. Cell Death Dis. 2011;2(9):e199. doi: 10.1038/cddis.2011.86.318690421881601
]Open DOISearch in Google Scholar
[
54. Li J, Yuan J. Caspases in apoptosis and beyond. Oncogene. 2008;27(48):6194-206.10.1038/onc.2008.29718931687
]Search in Google Scholar
[
55. Wang LW, Li ZS, Zou DW, Jin ZD, Gao J, Xu GM. Metformin induces apoptosis of pancreatic cancer cells. World J Gastroenterol. 2008;14(47):7192-8.10.3748/wjg.14.7192498835619084933
]Search in Google Scholar
[
56. Isakovic A, Harhaji L, Stevanovic D, Markovic Z, Sumarac-Dumanovic M, Starcevic V, et al. Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosis. Cell Mol Life Sci. 2007;64(10):1290-302.10.1007/s00018-007-7080-417447005
]Search in Google Scholar
[
57. Gao ZY, Liu Z, Bi MH, Zhang JJ, Han ZQ, Han X, et al. Metformin induces apoptosis via a mitochondria-mediated pathway in human breast cancer cells in vitro. Exp Ther Med. 2016;11(5):1700-1706.10.3892/etm.2016.3143484052627168791
]Search in Google Scholar
[
58. Takahashi A, Kimura F, Yamanaka A, Takebayashi A, Kita N, Takahashi K, et al. Metformin impairs growth of endometrial cancer cells via cell cycle arrest and concomitant autophagy and apoptosis. Cancer Cell Int. 2014;14:53. doi: 10.1186/1475-2867-14-53.407040124966801
]Open DOISearch in Google Scholar
[
59. Jang JH, Sung EG, Song IH, Lee TJ, Kim JY. Metformin induces caspase-dependent and caspase-independent apoptosis in human bladder cancer T24 cells. Anticancer Drugs. 2020;31(7):655-662.10.1097/CAD.0000000000000966736567032568826
]Search in Google Scholar
[
60. Cha JH, Yang WH, Xia W, Wei Y, Chan LC, Lim SO, et al. Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PDL1. Mol Cell. 2018;71(4):606-620.10.1016/j.molcel.2018.07.030678649530118680
]Search in Google Scholar
[
61. Yu W, Hua Y, Qiu H. et al. PD-L1 promotes tumor growth and progression by activating WIP and β-catenin signaling pathways and predicts poor prognosis in lung cancer. Cell Death Dis 11, 506 (2020).10.1038/s41419-020-2701-z733845732632098
]Search in Google Scholar
[
62. Jovanovic M, Gajovic N, Lukic M, Popovic A, Jovanovic IP. Synergism of PDL/PD1 and IL33/ST2 axis in tumor immunology. Ser J Exp Clin Res. 2019;20(3):223-228.10.2478/sjecr-2018-0033
]Search in Google Scholar
[
63. Jovanovic M, Gajovic N, Jurisevic M, Sekulic S, Arsenijevic N, Jocic M, et al. Anti PD1 therapy activates tumoricidic properties of NKT cells and contributes to overall deceleration of tumor progression in a model of murine mammary carcinoma. Vojnosanitpregl. 2021; doi: 10.2298/VSP210126039J
]Open DOISearch in Google Scholar
[
64. Jovanovic M, Geller D, Gajovic N, Jurisevic M, Arsenijevic N, Jovanovic M, et al. Dual blockage of PD-L/PD-1 and IL33/ST2 axes slows tumor growth and improves antitumor immunity by boosting NK cells. Life Sciences. 2022;289:120214. doi.org/10.1016/j.lfs.2021.12021410.1016/j.lfs.2021.12021434890591
]Search in Google Scholar
[
65. Han Y, Liu D, Li L. PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020;10(3):727-742.
]Search in Google Scholar
[
66. Zhang JJ, Zhang QS, Li ZQ, Zhou JW, Du J. Metformin attenuates PD-L1 expression through activating Hippo signaling pathway in colorectal cancer cells. Am J Transl Res. 2019;11(11):6965-6976.
]Search in Google Scholar
[
67. Xue J, Li L, Li N, Li F, Qin X, Li T, et al. Metformin suppresses cancer cell growth in endometrial carcinoma by inhibiting PD-L1. Eur J Pharmacol. 2019;15;859:172541. doi: 10.1016/j.ejphar.2019.172541.31319067
]Open DOISearch in Google Scholar
[
68. Petty AJ, Yang Y. Tumor-associated macrophages: implications in cancer immunotherapy. Immunotherapy. 2017;9(3):289-302.10.2217/imt-2016-0135561905228231720
]Search in Google Scholar
[
69. Ding L, Liang G, Yao Z, Zhang J, Liu R, Chen H, et al. Metformin prevents cancer metastasis by inhibiting M2-like polarization of tumor associated macrophages. Oncotarget. 2015;6(34):36441-55.10.18632/oncotarget.5541474218826497364
]Search in Google Scholar
[
70. Saito A, Kitayama J, Horie H, Koinuma K, Ohzawa H, Yamaguchi H, et al. Metformin changes the immune microenvironment of colorectal cancer in patients with type 2 diabetes mellitus. Cancer Sci. 2020;111(11):4012-4020.10.1111/cas.14615764804232794612
]Search in Google Scholar
[
71. Chiang CF, Chao TT, Su YF, Hsu CC, Chien CY, Chiu KC, et al. Metformin-treated cancer cells modulate macrophage polarization through AMPK-NF-κB signaling. Oncotarget. 2017;8(13):20706-20718.10.18632/oncotarget.14982540053828157701
]Search in Google Scholar
[
72. Ma Q, Gu JT, Wang B, Feng J, Yang L, Kang XW, et al. PlGF signaling and macrophage repolarization contribute to the anti-neoplastic effect of metformin. Eur J Pharmacol. 2019; 15;863:172696. doi: 10.1016/j.ejphar.2019.172696.31562866
]Open DOISearch in Google Scholar
[
73. St Paul M, Ohashi PS. The Roles of CD8+ T Cell Subsets in Antitumor Immunity. Trends Cell Biol. 2020;30(9):695-704.10.1016/j.tcb.2020.06.00332624246
]Search in Google Scholar
[
74. Blank CU, Haining WN, Held W, Hogan PG, Kallies A, Lugli E, et al. Defining ‘T cell exhaustion’. Nat Rev Immunol. 2019;19(11):665-674.10.1038/s41577-019-0221-9728644131570879
]Search in Google Scholar
[
75. Watanabe M, Eikawa S, Shien K, Yamamoto H, Shien T, Soh J, et al. Abstract 5592: metformin improves immune function of exhausted peripheral CD8+ T cells derived from cancer patients. Cancer Res. 2017; 77(13 Suppl):5592–5592.10.1158/1538-7445.AM2017-5592
]Search in Google Scholar
[
76. Eikawa S, Nishida M, Mizukami S, Yamazaki C, Nakayama E, Udono H. Immune-mediated antitumor effect by type 2 diabetes drug, metformin. Proc Natl Acad Sci U S A. 2015;112(6):1809-14.10.1073/pnas.1417636112433073325624476
]Search in Google Scholar
[
77. Zhang Z, Li F, Tian Y, Cao L, Gao Q, Zhang C, et al. Metformin Enhances the Antitumor Activity of CD8+ T Lymphocytes via the AMPK-miR-107-Eomes-PD-1 Pathway. J Immunol. 2020;204(9):2575-2588.10.4049/jimmunol.190121332221038
]Search in Google Scholar
[
78. Kunisada Y, Eikawa S, Tomonobu N, Domae S, Uehara T, Hori S, et al. Attenuation of CD4+CD25+ Regulatory T Cells in the Tumor Microenvironment by Metformin, a Type 2 Diabetes Drug. EBioMedicine. 2017;25:154-164.10.1016/j.ebiom.2017.10.009570405329066174
]Search in Google Scholar
[
79. Ohue Y, Nishikawa H. Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target? Cancer Sci. 2019;110(7):2080-2089.10.1111/cas.14069660981331102428
]Search in Google Scholar
[
80. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299(5609):1057-61.10.1126/science.107949012522256
]Search in Google Scholar
[
81. Wei L, Luo Z, Li J, Li H, Liang Y, Li J, et al. Metformin inhibits proliferation and functions of regulatory T cells in acidic environment. 2019;39(12):1427-1435.
]Search in Google Scholar
[
82. Pereira FV, Melo ACL, Low JS, de Castro ÍA, Braga TT, Almeida DC, et al. Metformin exerts antitumor activity via induction of multiple death pathways in tumor cells and activation of a protective immune response. Oncotarget. 2018;9(40):25808-25825.10.18632/oncotarget.25380599525329899823
]Search in Google Scholar
[
83. Reiser J, Banerjee A. Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor Immune Response. J Immunol Res. 2016;2016:8941260. doi: 10.1155/2016/8941260.489344027314056
]Open DOISearch in Google Scholar
[
84. Zhao D, Long XD, Lu TF, Wang T, Zhang WW, Liu YX, et al. Metformin decreases IL-22 secretion to suppress tumor growth in an orthotopic mouse model of hepatocellular carcinoma. Int J Cancer. 2015;136(11):25 56-65.10.1002/ijc.2930525370454
]Search in Google Scholar
[
85. Peng Y, Gao X, Yang J. et al. Interleukin-22 Promotes T Helper 1 (Th1)/Th17 Immunity in Chlamydial Lung Infection. Mol Med 20, 2014; 109–119.10.2119/molmed.2013.00115396039724531835
]Search in Google Scholar
[
86. Li L, Wang L, Li J, Fan Z, Yang L, Zhang Z, et al. Metformin-Induced Reduction of CD39 and CD73 Blocks Myeloid-Derived Suppressor Cell Activity in Patients with Ovarian Cancer. Cancer Res. 2018;78(7):1779-1791.10.1158/0008-5472.CAN-17-2460588258929374065
]Search in Google Scholar
[
87. Xu P, Yin K, Tang X, Tian J, Zhang Y, Ma J, et al. Metformin inhibits the function of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. Biomed Pharmacother. 2019;120:109458. doi: 10.1016/j.biopha.2019.109458.31550676
]Open DOISearch in Google Scholar
[
88. Hirayama T, Nagata Y, Nishida M, Matsuo M, Kobayashi S, Yoneda A, et al. Metformin Prevents Peritoneal Dissemination via Immune-suppressive Cells in the Tumor Microenvironment. Anticancer Res. 2019;39(9):4699-4709.10.21873/anticanres.1365231519569
]Search in Google Scholar
[
89. Qin G, Lian J, Huang L, Zhao Q, Liu S, Zhang Z, et al. Metformin blocks myeloid-derived suppressor cell accumulation through AMPK-DACH1-CXCL1 axis. Oncoimmunology. 2018;7(7):e1442167. doi: 10.1080/21624 02X.2018.1442167.
]Open DOISearch in Google Scholar
[
90. Uehara T, Eikawa S, Nishida M, Kunisada Y, Yoshida A, Fujiwara T, et al. Metformin induces CD11b+-cellmediated growth inhibition of an osteosarcoma: implications for metabolic reprogramming of myeloid cells and anti-tumor effects. Int Immunol. 2019;31(4):187-198.10.1093/intimm/dxy079644044130508092
]Search in Google Scholar
[
91. Filipazzi P, Huber V, Rivoltini L. Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol Immunother. 2012;61(2):255-263.10.1007/s00262-011-1161-922120756
]Search in Google Scholar
[
92. Ostrand-Rosenberg S. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother. 2010;59(10):1593-600.10.1007/s00262-010-0855-8370626120414655
]Search in Google Scholar
[
93. Gajovic N, Jurisevic M, Pantic J, Radosavljevic G, Arsenijevic N, Lukic ML, et al. Attenuation of NK cells facilitates mammary tumor growth in streptozotocin-induced diabetes in mice. Endocrine-related cancer 2018; 25: 493-507.10.1530/ERC-17-052929459428
]Search in Google Scholar
[
94. Lee S, Margolin K. Cytokines in cancer immunotherapy. Cancers (Basel). 2011;3(4):3856-93.10.3390/cancers3043856376340024213115
]Search in Google Scholar
[
95. Karadeniz Z, Aynacıoğlu AŞ, Bilir A, Tuna MY. Inhibition of midkine by metformin can contribute to its anticancer effects in malignancies: A proposal mechanism of action of metformin in context of endometrial cancer prevention and therapy. Med Hypotheses. 2020;134:e109420. doi: 10.1016/j.mehy.2019.109420.31634770
]Open DOISearch in Google Scholar
[
96. Filippou PS, Karagiannis GS, Constantinidou A. Midkine (MDK) growth factor: a key player in cancer progression and a promising therapeutic target. Oncogene. 2020;39(10):2040-2054.10.1038/s41388-019-1124-831801970
]Search in Google Scholar
[
97. Mishra A. K., Dingli D. Metformin inhibits IL-6 signaling by decreasing IL-6R expression on multiple myeloma cells. Leukemia, 2019;33(11), 2695-2709.10.1038/s41375-019-0470-430988378
]Search in Google Scholar
[
98. Kumari N, Dwarakanath BS, Das A, Bhatt AN. Role of interleukin-6 in cancer progression and therapeutic resistance. Tumour Biol. 2016;37(9):11553-11572.10.1007/s13277-016-5098-727260630
]Search in Google Scholar
[
99. Kang S, Kim BR, Kang MH, Kim DY, Lee DH, Oh SC, et al. Anti-metastatic effect of metformin via repression of interleukin 6-induced epithelial-mesenchymal transition in human colon cancer cells. PLoS One. 2018;13(10):e0205449. doi: 10.1371/journal.pone.0205449.618137530308035
]Open DOISearch in Google Scholar
[
100.Shuchen Gu, Xin-Hua Feng. TGF-β signaling in cancer, Acta Biochimica et BiophysicaSinica, 2018;50(10):941-949.
]Search in Google Scholar
[
101.Gajovic N, Jovanovic I, Ilic A, Jeremic N, Jakovljevic V, Arsenijevic N, et al. Diabetes mellitus directs NKT cells toward type 2 and regulatory phenotype Ser J Exp Clin Res. 2016; 17 (1): 35-41.
]Search in Google Scholar
[
102.Xiao H, Zhang J, Xu Z, et al. Metformin is a novel suppressor for transforming growth factor (TGF)-β1. Sci Rep. 2016;6:28597. doi: 10.1038/srep28597492385827349853
]Open DOISearch in Google Scholar
[
103.Leonel C, Borin TF, de Carvalho Ferreira L, Moschetta MG, Bajgelman MC, Viloria-Petit AM, et al. Inhibition of Epithelial-Mesenchymal Transition and Metastasis by Combined TGFbeta Knockdown and Metformin Treatment in a Canine Mammary Cancer Xenograft Model. J Mammary Gland Biol Neoplasia. 2017;22(1):27-41.10.1007/s10911-016-9370-728078601
]Search in Google Scholar
[
104.Song Y, Chen Y, Li Y, Lyu X, Cui J, Cheng Y, et al. Metformin inhibits TGF-β1-induced epithelial-to-mesenchymal transition-like process and stem-like properties in GBM via AKT/mTOR/ZEB1 pathway. Oncotarget. 2017;9(6):7023-7035.10.18632/oncotarget.23317580553329467947
]Search in Google Scholar
[
105.Chengye W, Yu T, Ping S, Deguang S, Keyun W, Yan W, et al. Metformin reverses bFGF-induced epithelialmesenchymal transition in HCC cells. Oncotarget. 2017;8(61):104247-104257.10.18632/oncotarget.22200573280329262637
]Search in Google Scholar